163 related articles for article (PubMed ID: 32147907)
1. An update on the implications of cyclin D1 in melanomas.
González-Ruiz L; González-Moles MÁ; González-Ruiz I; Ruiz-Ávila I; Ayén Á; Ramos-García P
Pigment Cell Melanoma Res; 2020 Nov; 33(6):788-805. PubMed ID: 32147907
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic application of cyclin D1 fluorescent in situ hybridization for histologically undetermined early lesions of acral melanoma in situ: A case series.
Cho-Vega JH; Cao T; Ledon J; Moller M; Avisar E; Elgart G; Tan JH; Fan YS; Grichnik JM
Ann Diagn Pathol; 2021 Feb; 50():151681. PubMed ID: 33341705
[TBL] [Abstract][Full Text] [Related]
4. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).
Zhu Y; Wen X; Zhao P
Med Sci Monit; 2018 Jun; 24():3679-3692. PubMed ID: 29858490
[TBL] [Abstract][Full Text] [Related]
6. An update on the implications of cyclin D1 in oral carcinogenesis.
Ramos-García P; Gil-Montoya JA; Scully C; Ayén A; González-Ruiz L; Navarro-Triviño FJ; González-Moles MA
Oral Dis; 2017 Oct; 23(7):897-912. PubMed ID: 27973759
[TBL] [Abstract][Full Text] [Related]
7. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
9. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma.
Utikal J; Udart M; Leiter U; Peter RU; Krähn G
Int J Oncol; 2005 Mar; 26(3):597-605. PubMed ID: 15703813
[TBL] [Abstract][Full Text] [Related]
10. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
11. alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
Hu R; Aplin AE
Pigment Cell Melanoma Res; 2010 Apr; 23(2):201-9. PubMed ID: 20067552
[TBL] [Abstract][Full Text] [Related]
12. Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer.
Utikal J; Udart M; Leiter U; Kaskel P; Peter RU; Krähn G
Cancer Lett; 2005 Mar; 219(2):197-204. PubMed ID: 15723720
[TBL] [Abstract][Full Text] [Related]
13. Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas.
Nai G; Marques M
Pathol Res Pract; 2011 Mar; 207(3):174-81. PubMed ID: 21300445
[TBL] [Abstract][Full Text] [Related]
14. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 is a candidate oncogene in cutaneous melanoma.
Sauter ER; Yeo UC; von Stemm A; Zhu W; Litwin S; Tichansky DS; Pistritto G; Nesbit M; Pinkel D; Herlyn M; Bastian BC
Cancer Res; 2002 Jun; 62(11):3200-6. PubMed ID: 12036934
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin D1 and p53 protein in various malignant skin tumors.
Inohara S; Kitagawa K; Kitano Y
Dermatology; 1996; 192(2):94-8. PubMed ID: 8829518
[TBL] [Abstract][Full Text] [Related]
19. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
20. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.
Kaufmann C; Kempf W; Mangana J; Cheng P; Emberger M; Lang R; Kaiser AK; Lattmann E; Levesque M; Dummer R; Koelblinger P
Histopathology; 2020 Sep; 77(3):460-470. PubMed ID: 32374893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
